NCT01994382 2022-04-05Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHLAlexion Pharmaceuticals, Inc.Phase 1/2 Completed260 enrolled 33 charts
NCT00379587 2014-03-19Rituximab for Prevention of Chronic GVHDDana-Farber Cancer InstitutePhase 1/2 Completed65 enrolled 9 charts